AVANIA
16.3.2023 14:01:40 CET | Business Wire | Press release
Avania, a leading, global medical technology contract research organization (CRO), today announced its appointment of Todd M. Pope as the new chairman of the board of directors. Todd brings 30 years of technology, medical device, and leadership experience across large cap and startup MedTech and was named to TIME Magazine’s 2018 list of 50 Most Influential People in Healthcare. Having spent the last 20 years in CEO roles in both private and public companies, he also currently serves as the chairman of the board of directors of AdvaMed ACCEL, the division within AdvaMed dedicated to addressing the unique needs of small and startup medical technology manufacturers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230316005199/en/
Avania Names Todd M. Pope New Chairman of the Board (Photo: Business Wire)
“I am very pleased to take on this role at such a dynamic time and support Avania on its growth journey,” said Pope. “After a rewarding career leading companies in the MedTech industry, I am motivated by the opportunity to work alongside the senior management team to execute on Avania’s transformational business strategy.”
Todd’s previous roles included global president of Johnson & Johnson Cordis, president and CEO of TransEnterix, as well as other senior executive positions within the MedTech space. Todd is currently director of the boards of Distalmotion and Humacyte, and a partner at Revival Healthcare Capital.
“Todd’s long history of leadership, coupled with his deep operating and commercial experience in the MedTech space makes him an ideal person for this role,” said Sapna Hornyak, president and CEO of Avania. “I look forward to working closely with Todd to ensure Avania continues to make a positive impact for all stakeholders, including Avania’s customers, our people, and the MedTech community. The senior management team along with the board of directors are excited about the future and look forward to bringing Avania to the next new phase with our new chairman.”
“We are very excited to be working with Todd,” added Edouard Pillot, managing partner, and Enrico Grasso, partner of Astorg Mid-Cap, which has majority interest in Avania. “He brings a wealth of MedTech industry experience and relationships that will provide invaluable connections with customers as well as insights into their evolving needs, and how Avania can best serve them. Todd’s leadership experience, with small and large businesses, will also support Avania as it grows and scales.”
About Avania
Avania is a leading, global full-service contract research organization focused on the management of clinical studies for medical devices, IVDs, biologics, and device-drug combination products internationally. Avania supports products from the first-in-human phase through the post-market phase with the same customized approach. When you need to advance your medical technology, it takes Avania. Avania’s vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230316005199/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead29.1.2026 07:37:00 CET | Press release
Year-to-Date Revenue Declined by 2.8% at Constant Exchange Rate (CER), 3.3% atActual Exchange Rates (AER);Impact of VYVANSE® Generics is Tapering OffCore Operating Profit Declined by 3.4% at both CER and AER Year to DateReported Operating Profit Increased by 1.2% at AER Year to Date, Lower Restructuring Expenses More Than Offset Impairment Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incremental Growth & Launch Products revenue and VYVANSE erosion is narrowing, and operational efficiencies drove year-on-year reductions in operating expenses, including R&D. The company raised its full-year forecasts based on cost discipline and FX tailwind, while its Revenue Management Guidance has been updated primarily due to the impact of VYVANSE generics. Takeda is positioned for long-term growth and has multiple late-stage programs with multibillion-dollar peak revenue potential. Follow
Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty29.1.2026 07:00:00 CET | Press release
‘Wake Up To Restylane®’ is a global campaign designed to meet the rising demand for natural-looking always-on results, helping people wake up looking refreshed and rested, and reframes Restylane treatments from a clinical procedure into an always-on beauty regimen Backed by 30 years of science, the Restylane portfolio is the only hyaluronic acid (HA) range offering four distinct technologies, designed to deliver personalized natural-looking outcomes that provide contour, definition, and hydration, with HA closest to the skin’s own1-7 This launch builds on new clinical data presented at the International Master Course on Aging Science (IMCAS) World Congress 2026, confirming Restylane’s proven efficacy and versatility across multiple facial areas and the décolletage8-11 Galderma (SIX: GALD), the pure-play dermatology category leader, has launched ‘Wake Up To Restylane’, a global campaign that showcases Restylane as an everyday beauty ally. Aligned with the growing desire for effortless,
Ubitus Partners with Maizuru City, Kyoto to Launch AI Data Center Project, Advancing the Deployment of a Top-Tier AI GPU Center in Japan29.1.2026 07:00:00 CET | Press release
Ubitus K.K. (Headquarters: Shinjuku, Tokyo; Representative Director & CEO: Wesley Kuo), a global leader in cloud streaming and AI solutions, today announced that it will hold a land signing ceremony and press conference with Maizuru City, Kyoto Prefecture, on January 29, 2026. At the event, Ubitus will officially unveil its comprehensive plan to construct an AI Data Center in Maizuru City, marking the company’s transition into the physical construction phase of its initiative to build a top-tier AI GPU center in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128944842/en/ Ubitus will launch its Maizuru City AI Data Center project on January 29, marking the first step toward building a top-tier AI GPU center in Japan. Powered by NVIDIA Blackwell GPUs and NeoCloud, the project strengthens Japan’s AI infrastructure and regional development. This land agreement represents the first major milestone following Ubitus’ sel
Lattice to Showcase Advanced Edge AI Solutions at the FPGA-forum 202628.1.2026 22:00:00 CET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its exhibition plan for the upcoming FPGA-forum 2026 taking place February 11 – 12, 2026 in Trondheim, Norway. As part of the event, Lattice Corporate Vice President of Software Solutions and Applications Engineering Eleena Ong will deliver a keynote presentation exploring how rapidly maturing AI technologies can turn FPGA platforms into innovation canvases for a much broader range of developers, sparking new application possibilities. Lattice will also deliver a technical presentation and host a demo showcase focused on how its low power FPGA solutions are advancing connectivity and edge AI applications. Who: Lattice Semiconductor What / When (GMT+1): Lattice Demo Showcase (Table #3), Feb 11-12 Keynote Feb. 11, 9:30 a.m. “Unlocking the Next Wave of FPGA Innovators with Generative and Agentic AI” Technical Presentation Feb. 12, 10 a.m. “Smaller. Cooler. Smarter: Lattice FPGAs’ Path to Uncompromised
Egon Zehnder Elects German Herrera as New Chair28.1.2026 20:01:00 CET | Press release
Herrera succeeds Michael Ensser, who will remain an active member of the Firm after his term in a planned transition. Egon Zehnder, the world’s premier leadership advisory firm, today announced that, in accordance with its established governance and three-year election cycle, German Herrera has been elected as the Firm’s next Chair by its worldwide partnership. Herrera will assume the role effective March 1, 2026. He will succeed Michael Ensser, who has held the position since 2022, in a planned succession at the conclusion of his regular term. Herrera joined the Firm in 1998 in Bogotá and has helped shape the Firm’s global presence, taking on a broad range of leadership roles, from co-leading the Global Family Business Advisory Practice to serving on the Executive Committee and the Market Council. Most recently, Herrera has guided Egon Zehnder’s U.S. market through a period of impressive growth and transformation, which today includes 15 offices and more than 150 consultants. As the f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom